Sicart Associates
GH icon

Sicart Associates’s Guardant Health GH Stock Holding History

Sicart Associates’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.7M Sell
181,030
-49,985
-22% -$8.17M 6.96% 3
2026
Q2 		$34.7M Buy
231,015
+912
+0.4% +$99.2K 8.49% 2
2026
Q1 		$21.3M Buy
230,103
+1,900
+0.8% +$191K 5.46% 3
2025
Q4 		$23.3M Sell
228,203
-1,880
-0.8% -$168K 6.18% 3
2025
Q3 		$14.4M Buy
230,083
+64,628
+39% +$3.52M 3.89% 5
2025
Q2 		$8.61M Buy
165,455
+27,862
+20% +$1.24M 3.01% 11
2025
Q1 		$5.86M Sell
137,593
-2,740
-2% -$118K 2.03% 20
2024
Q4 		$4.29M Sell
140,333
-5,970
-4% -$168K 1.53% 28
2024
Q3 		$3.36M Buy
146,303
+320
+0.2% +$9.06K 1.18% 33
2024
Q2 		$4.22M Sell
145,983
-609
-0.4% -$14.2K 1.62% 28
2024
Q1 		$3.02M Buy
146,592
+53,639
+58% +$1.15M 1.11% 30
2023
Q4 		$2.51M Sell
92,953
-2,972
-3% -$78K 0.96% 34
2023
Q3 		$2.84M Buy
95,925
+2,955
+3% +$104K 1.12% 32
2023
Q2 		$3.33M Buy
92,970
+3,050
+3% +$87.6K 1.29% 30
2023
Q1 		$2.11M Sell
89,920
-8,070
-8% -$230K 0.82% 35
2022
Q4 		$2.67M Sell
97,990
-38,469
-28% -$1.76M 0.94% 33
2022
Q3 		$7.35M Sell
136,459
-1,430
-1% -$73.4K 2.61% 15
2022
Q2 		$5.56M Buy
137,889
+4,223
+3% +$209K 1.73% 24
2022
Q1 		$8.85M Buy
133,666
+91,783
+219% +$6.28M 2.29% 17
2021
Q4 		$4.2M Buy
41,883
+41
+0.1% +$4.24K 1.1% 29
2021
Q3 		$5.23M Buy
41,842
+1,322
+3% +$157K 1.43% 23
2021
Q2 		$5.03M Buy
+40,520
New +$5.45M 1.2% 31

Other funds holding GH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
AGF Management
AGF Management Toronto, Ontario, Canada $24.5B AUM 50.2% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $200B AUM 30.19% 1-Year Est. Return

Sicart Associates's GH Position: Q3 2026 in Review

Sicart Associates reduced its Guardant Health (GH) stake by 22% in Q3 2026, selling an estimated $8.17M and leaving 181,030 shares worth $28.7M. The position accounts for 6.96% of the portfolio, ranked #3.

Sicart Associates first reported a position in GH in Q2 2021 and has held it in 22 quarters since. The position peaked at $34.7M in Q2 2026. 350 funds tracked by Wall St. Rank hold GH as of Q3 2026.

  • Sicart Associates held 181,030 shares of Guardant Health worth $28.7M as of Q3 2026.
  • Sicart Associates sold 49,985 Guardant Health shares in Q3 2026, an estimated $8.17M.
  • Guardant Health made up 6.96% of Sicart Associates's portfolio in Q3 2026, its #3 holding.
  • Sicart Associates first reported a position in Guardant Health in Q2 2021 and has held it in 22 quarters since.
  • Sicart Associates's Guardant Health position peaked at $34.7M in Q2 2026.
  • 350 funds tracked by Wall St. Rank held Guardant Health as of Q3 2026.

Based on Sicart Associates's 13F filing for Q3 2026, filed 29 Oct 2026.